5609-49-4|Tetragastrin HCl|(S)-3-((S)-2-((S)-2-amino-3-(1H-indol-3-yl)propanamido)-4-(methylthio)butanamido)-4-oxo-4-(((S)-1-oxo-1-(phenylamino)propan-2-yl)amino)butanoic acid hydrochloride|-范德生物科技公司

Tetragastrin HCl

NMR下载 COA and HPLC MSDS下载
names：
(S)-3-((S)-2-((S)-2-amino-3-(1H-indol-3-yl)propanamido)-4-(methylthio)butanamido)-4-oxo-4-(((S)-1-oxo-1-(phenylamino)propan-2-yl)amino)butanoic acid hydrochloride
CAS号：
5609-49-4
MDL Number：
MF(分子式)： C29H37ClN6O6S MW(分子量)： 633.16
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(S)-3-((S)-2-((S)-2-amino-3-(1H-indol-3-yl)propanamido)-4-(methylthio)butanamido)-4-oxo-4-(((S)-1-oxo-1-(phenylamino)propan-2-yl)amino)butanoic acid hydrochloride
英文别名	Tetragastrin hydrochloride; Tetragastrin HCl; Trp-Met-Asp-Phe hydrochloride;
CAS号	5609-49-4
Inchi	InChI=1S/C29H36N6O6S.ClH/c1-17(26(38)33-19-8-4-3-5-9-19)32-29(41)24(15-25(36)37)35-28(40)23(12-13-42-2)34-27(39)21(30)14-18-16-31-22-11-7-6-10-20(18)22;/h3-11,16-17,21,23-24,31H,12-15,30H2,1-2H3,(H,32,41)(H,33,38)(H,34,39)(H,35,40)(H,36,37);1H/t17-,21-,23-,24-;/m0./s1
InchiKey	WHGNESKICGIAEC-WCFNAMMKSA-N
分子式 Formula	C29H37ClN6O6S
分子量 Molecular Weight	633.16
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Tetragastrin HCl(CAS:5609-49-4):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Tetragastrin HCl is the HCl salt of Tetragastrin, the C-terminal tetrapeptide of gastrin. It is the smallest peptide fragment of gastrin which has the same physiological and pharmacological activity as gastrin.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Tenma T, Yodoya E, Tashima S, Fujita T, Murakami M, Yamamoto A, Muranishi S. Development of new lipophilic derivatives of tetragastrin: physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats. Pharm Res. 1993 Oct;10(10):1488-92. PubMed PMID: 8272412.

[2]Komuro Y, Ishihara K, Ohara S, Saigenji K, Hotta K. Effects of tetragastrin on mucus glycoprotein in rat gastric mucosal protection. Gastroenterol Jpn. 1992 Oct;27(5):597-603. PubMed PMID: 1385248.

[3] Tatsuta M, Iishi H, Yamamura H, Taniguchi H. Inhibition by tetragastrin of experimental carcinogenesis in rat colon: effect of wheat bran consumption. Int J Cancer. 1988 Feb 15;41(2):239-42. PubMed PMID: 2828245.

[4] Tatsuta M, Iishi H, Baba M, Taniguchi H. Effect of 6-hydroxydopamine on gastric carcinogenesis and tetragastrin inhibition of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res. 1989 Aug 1;49(15):4199-203. PubMed PMID: 2501024.

[5] Tatsuta M, Iishi H, Yamamura H, Taniguchi H. Enhancement by propranolol of the inhibitory effect of tetragastrin on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res. 1987 Jan 1;47(1):111-4. PubMed PMID: 3791197.

6: Setoh K, Murakami M, Araki N, Fujita T, Yamamoto A, Muranishi S. Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids. J Pharm Pharmacol. 1995 Oct;47(10):808-11. PubMed PMID: 8583347.7: Komuro Y, Ishihara K, Kojima Y, Saigenji K, Hotta K. Distinct effects of tetragastrin in rat gastroduodenal mucosa on mucin content and mucosal protective action against histamine-induced injury. Dig Dis Sci. 1998 May;43(5):1050-6. PubMed PMID: 9590421.8: Tatsuta M, Yamamura H, Baba M, Yamamoto R, Iishi H, Taniguchi H. Inhibitory effect of prolonged administration of tetragastrin on experimentally induced intestinal metaplasia in Wistar rats. Cancer. 1988 May 15;61(10):2051-6. PubMed PMID: 3359403.9: Tatsuta M, Iishi H, Yamamura H, Yamamoto R, Taniguchi H. Enhancement by tetragastrin of experimental induction of gastric epithelium in the duodenum. Gut. 1989 Mar;30(3):311-5. PubMed PMID: 2707631; PubMed Central PMCID: PMC1378451.10: Tatsuta M, Iishi H, Baba M, Taniguchi H. Effect of ornithine decarboxylase inhibitor on tetragastrin treatment of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1990 Feb 15;45(2):308-11. PubMed PMID: 2105911.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开